积极应对高血压患者多种药物不耐受带来的临床困境

刘靖

doi:10.16439/j.issn.1673-7245.2025-0245

中华高血压杂志（中英文） ›› 2026, Vol. 34 ›› Issue (6) : 501 -502. DOI: 10.16439/j.issn.1673-7245.2025-0245

述评

积极应对高血压患者多种药物不耐受带来的临床困境

刘靖

作者信息 +

Actively confronting the clinical dilemmas of multiple drug intolerance in hypertensive patients

Jing LIU

Author information +

文章历史 +

PDF (607K)

摘要

多种降压药不耐受（MDI）通常是指对至少三种不同类型的降压药产生难以耐受的不良反应，但没有明确的免疫学机制参与。MDI 在临床中客观存在，但长期被忽视。患者治疗依从性下降，血压控制较为棘手。患者多辗转就诊，带来巨大的心理及社会负担。分析这部分特定人群的临床特征，梳理导致 MDI 的可能因素，制定个体化治疗策略，有助于改善血压控制、降低疾病负担。

Abstract

Multiple drug intolerance (MDI) usually refers to the intolerable adverse reactions of at least three different types of antihypertensive drugs, while there is no clear immunological mechanism involved. MDI exists objectively in clinical practice, but has been neglected for a long time. The patient's treatment compliance decreased, and blood pressure control was difficult. Patients often return multiple times for repeated consultations, bringing huge psychological and social burden. Analyzing the clinical characteristics of this specific population, sorting out the possible factors leading to MDI, and formulating individualized treatment strategies will help to improve blood pressure control and reduce disease burden.

关键词

多种药物 / 不耐受 / 高血压

Key words

multiple drugs / intolerance / hypertension

引用本文

引用格式 ▾

[Author(id=1292545485002027790, tenantId=1045748351789510663, journalId=1155139928303341770, articleId=1292542241722552620, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1292545485056553746, tenantId=1045748351789510663, journalId=1155139928303341770, articleId=1292542241722552620, authorId=1292545485002027790, language=EN, stringName=Jing LIU, firstName=Jing, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Hypertension Department Peking University People’s Hospital , Beijing, China 100044, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1292545485106885397, tenantId=1045748351789510663, journalId=1155139928303341770, articleId=1292542241722552620, authorId=1292545485002027790, language=CN, stringName=刘靖, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京大学人民医院高血压科，北京 100044, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1292545484934918921, tenantId=1045748351789510663, journalId=1155139928303341770, articleId=1292542241722552620, xref=null, ext=[AuthorCompanyExt(id=1292545484947501833, tenantId=1045748351789510663, journalId=1155139928303341770, articleId=1292542241722552620, companyId=1292545484934918921, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Hypertension Department Peking University People’s Hospital , Beijing, China 100044), AuthorCompanyExt(id=1292545484960084747, tenantId=1045748351789510663, journalId=1155139928303341770, articleId=1292542241722552620, companyId=1292545484934918921, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京大学人民医院高血压科，北京 100044)])])] 刘靖. 积极应对高血压患者多种药物不耐受带来的临床困境[J]. 中华高血压杂志（中英文）, 2026, 34(6): 501-502 DOI:10.16439/j.issn.1673-7245.2025-0245

登录浏览全文

4963

注册一个新账户忘记密码

参考文献

原文顺序 | 出版日期 | 本文引用

[1]	World Health Organization . Global report on hypertension: the race against a silent killer[R/OL]. [2024—04—16]. https://www.who.int/publications/i/item/9789240081062.

[2]	Coca A, Whelton SP, Camafort M, et al. Single—pill combination for treatment of hypertension: just a matter of practicality or is there a real clinical benefit?[J]. Eur J Intern Med, 2024, 126: 16-25.

[3]	Okeahialam BN . Multidrug intolerance in the treatment of hypertension: result from an audit of a specialized hypertension service[J]. Ther Adv Drug Saf, 2017, 8(8): 253-258.

[4]	Polaczyk M, Olszanecka A, Wojciechowska W, et al. Multiple drug intolerance in patients with arterial hypertension: prevalence and determining factors[J]. Pol Arch Intern Med, 2023, 133(3): 16399.

[5]	Blumenthal KG, Li Y, Acker WW, et al. Multiple drug intolerance syndrome and multiple drug allergy syndrome: epidemiology and associations with anxiety and depression[J]. Allergy, 2018, 73(10): 2012-2023.

[6]	Macy E, Ho NJ . Multiple drug intolerance syndrome: prevalence, clinical characteristics, and management[J]. Ann Allergy Asthma Immunol, 2012, 108(2): 88-93.

[7]	Fasano C, Palermiti A, Rabbia F, et al. Clinical characteristics of hypertensive patients with multiple drug intolerance[J]. J Hypertens, 2025, 43(Suppl 1): e2-e3.

[8]	刘靖, 北京高血压防治协会心血管代谢医学专业委员会 . 可乐定控释贴剂在高血压治疗中应用的专家共识[J]. 慢性病学杂志, 2022, 23(4): 4-7.

[9]	Parvan R, Aboumsallem JP, Meijers WC, et al. Innovative hypertension treatments: transitioning from conventional therapies to siRNA—based solutions[J]. Eur J Pharmacol, 2024, 985: 177110.

[10]	Cluett JL, Blazek O, Brown AL, et al. Renal denervation for the treatment of hypertension: a scientific statement from the American Heart Association[J]. Hypertension, 2024, 81(10): e135-e148.

[11]	Fisher N, Kirtane AJ . Renal denervation for hypertension[J]. Nat Rev Cardiol, 2025, 22(9): 664-674.

[12]	Drucker DJ . GLP—1—based therapies for diabetes, obesity and beyond[J]. Nat Rev Drug Discov, 2025, 24(8): 631-650.

[13]	Samson R, Milligan G, Lewine E, et al. Effect of sleeve gastrectomy on hypertension[J]. J Am Soc Hypertens, 2018, 12(11): e19-e25.

[14]	Ebadinejad A, Shahshahani M, Hosseinpanah F, et al. Comparison of hypertension remission and relapse after sleeve gastrectomy and one—anastomosis gastric bypass: a prospective cohort study[J]. Hypertens Res, 2023, 46(5): 1287-1296.